Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LL-IL-12D
- Development stage
- Preclinical
- Lead developer
- Xinjiang University
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal
01
Overview
LL-IL-12D is an experimental recombinant *Lactococcus lactis* (L. lactis) strain engineered to serve as a mucosal delivery vehicle for Interleukin-12 (IL-12) genetic material. It contains a eukaryotic expression cassette with the cDNA of mouse IL-12 (IL-12D). When administered intranasally, this food-grade dairy microorganism delivers the DNA to mammalian cells, leading to the local production of IL-12 protein. IL-12 acts as a potent molecular adjuvant, enhancing antigen-specific cellular immune responses, particularly cytotoxic T-lymphocyte (CTL) activity and interferon-gamma (IFN-γ) production. It has been studied primarily in the context of therapeutic vaccines for HPV-16-associated tumors, often in combination with strains expressing the E7 oncogenic protein to overcome the weak immunogenicity of tumor antigens.
- Other names
- Lactococcus lactis carrying IL-12 DNALL-mIL-12DLL-mIL12DLL-mIL 12D
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on LL-IL-12D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LL-IL-12D.